Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other financing activities: 2023-2024

Historic Other financing activities for Contineum Therapeutics (CTNM) over the last 1 years, with Mar 2024 value amounting to $140,000.

  • Contineum Therapeutics' Other financing activities rose 2700.00% to $140,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $157,000, marking a year-over-year change of. This contributed to the annual value of $22,000 for FY2023, which is N/A change from last year.
  • Per Contineum Therapeutics' latest filing, its Other financing activities stood at $140,000 for Q1 2024, which was up 13,900.00% from $1,000 recorded in Q4 2023.
  • Over the past 5 years, Contineum Therapeutics' Other financing activities peaked at $140,000 during Q1 2024, and registered a low of $1,000 during Q4 2023.
  • Its 2-year average for Other financing activities is $32,400, with a median of $5,000 in 2023.
  • Data for Contineum Therapeutics' Other financing activities shows a peak YoY spiked of 2,700.00% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Contineum Therapeutics' Other financing activities stood at $1,000 in 2023, then spiked by 2,700.00% to $140,000 in 2024.
  • Its Other financing activities stands at $140,000 for Q1 2024, versus $1,000 for Q4 2023 and $2,000 for Q3 2023.